Bio

Bio


Dr. Hong specializes in the diagnosis, evalaution and management of all rheumatologic diseases. She has a special interest in rheumatologic disease manifestations in patients with cancer and receiving cancer treatments. She collaborates with researchers to recruit patients for clinical trials and works with a research coordinator to collect blood and patient demographic information to study the effects of rheumatoid arthritis on cardiovascular disease. She has received additional training in the use of musculoskeletal ultrasound to evaluate and treat patients who may benefit from diagnostic ultrasound or ultrasound guided interventions.

Clinical Focus


  • Rheumatology

Academic Appointments


Professional Education


  • Fellowship:Stanford University School of Medicine - Office of Graduate Affairs - Postdoctoral AffairsCA
  • Board Certification: Rheumatology, American Board of Internal Medicine (2014)
  • Residency:University Medical Dental New Jersey (2012) NJ
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2011)
  • Medical Education:UMDNJ-NJMS (2008) NJ

Publications

All Publications


  • Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. International journal of clinical rheumatology Hong, J., Maron, D. J., Shirai, T., Weyand, C. M. 2015; 10 (5): 365-381

    Abstract

    Atherosclerosis is a complex inflammatory disease involving aberrant immune and tissue healing responses, which begins with endothelial dysfunction and ends with plaque development, instability and rupture. The increased risk for coronary artery disease in patients with rheumatologic diseases highlights how aberrancy in the innate and adaptive immune system may be central to development of both disease states and that atherosclerosis may be on a spectrum of immune-mediated conditions. Recognition of the tight association between chronic inflammatory disease and complications of atherosclerosis will impact the understanding of underlying pathogenic mechanisms and change diagnostic and therapeutic approaches in patients with rheumatologic syndromes as well as patients with coronary artery disease. In this review, we provide a summary of the role of the immune system in atherosclerosis, discuss the proposed mechanisms of accelerated atherosclerosis seen in association with rheumatologic diseases, evaluate the effect of immunosuppression on atherosclerosis and provide updates on available risk assessment tools, biomarkers and imaging modalities.

    View details for PubMedID 27042216

    View details for PubMedCentralID PMC4814165

  • Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab AMERICAN JOURNAL OF HEMATOLOGY Chao, M. P., Hong, J., Kunder, C., Lester, L., Schrier, S. L., Majeti, R. 2015; 90 (1): 78-81

    View details for DOI 10.1002/ajh.23791

    View details for Web of Science ID 000346771400022

    View details for PubMedID 24942207

  • Oralair (R): sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis EXPERT REVIEW OF CLINICAL IMMUNOLOGY Hong, J., Bielory, L. 2011; 7 (4): 437-444

    Abstract

    Oralair(®) is a sublingual grass pollen immunotherapy tablet that was authorized for use in Europe on 26 November 2009 and is currently in Phase III clinical trials in the USA. It is indicated for the management of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titer of the specific IgE to the grass pollen. Treatment is composed of an initiation phase (3-day dose escalation: 100 IR [index of reactivity] on day 1, 200 IR on day 2 and 300 IR on day 3) and a continuation phase at a dosage of 300 IR/day. Treatment is scheduled to start approximately 4 months before the actual start of the pollen season and should be continued throughout the season. The treatment should be prescribed and initiated by an experienced allergy specialist.

    View details for DOI 10.1586/ECI.11.36

    View details for Web of Science ID 000294535100015

    View details for PubMedID 21790286

  • Efficacy of intranasal corticosteroids for the ocular symptoms of allergic rhinitis: A systematic review ALLERGY AND ASTHMA PROCEEDINGS Hong, J., Bielory, B., Rosenberg, J. L., Bielory, L. 2011; 32 (1): 22-35

    Abstract

    Current treatment options for allergic rhinoconjunctivitis include topical antihistamines, vasoconstrictors, mast cell stabilizers, intranasal corticosteroids (INCS), and nonsteroidal anti-inflammatory drugs that are generally used as a supplement to oral or intranasal therapies, necessitating the use of multiple treatments for the different symptoms of allergic rhinitis (AR). To assess the efficacy of INCS for ocular symptoms (OS) of AR. A search was performed of clinical trials (n = 32) from 1973 to 2009 of English articles (Medline, Embase, and PubMed) using "intranasal corticosteroid," "allergic rhinitis," "ocular symptoms," "allergic conjunctivitis," and "rhinoconjunctivitis" as key words. Quality assessment for the 32 eligible studies was performed using the Jadad score. Statistical analysis for continuous data was done by weighted mean difference or standardized mean difference. Thirty-two trials were included and separated into three different groups. The overall weighted mean was obtained from the Jadad score and came out to 9.29 (95% CI, 8.7-9.88). For meta-analysis for total OS scores and individual symptoms (10 parallel studies) the weighted mean was 10.17 (95% CI, 9.34-11). In the parallel studies, meta-analysis of individual symptoms (nine studies) gave a weighted mean of 10.09 (95% CI, 9.55-10.63). For eye symptoms but no individual symptoms (13 studies), the weighted mean was 8.56 (95% CI, 7.66-9.46). To date, clinical studies conducted statistically showed the efficacy of INCS on the OS of AR as evidenced by the meta-analysis results for the studies reporting total OSs.

    View details for DOI 10.2500/aap.2011.32.3420

    View details for Web of Science ID 000286955000004

    View details for PubMedID 21262095

  • Allergy to ophthalmic preservatives CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY Hong, J., Bielory, L. 2009; 9 (5): 447-453

    Abstract

    The purpose of the present review is to examine the hypersensitivity reactions to preservatives in topical ophthalmic therapies.Ocular hypersensitivity reactions to different types of preservatives in different chemical classes of topical ophthalmic treatments reviewed in the literature include IgE-mast cell mediated, cell mediated and toxic. Quaternary ammoniums (benzalkonium chloride) are most commonly (8% reported cases in OVID and PubMED based searches) associated with irritant toxic reactions whereas the organomercurials (thimerosal) and the alcohols (chlorobutanol) have the highest association (19% of OVID and 14% of PubMED based searches and 20% of OVID and 11% of PubMED searches), respectively, with allergic responses although the term allergy for the 'alcohols' appears to be actually an irritant effect whereas the organomercurials appear to truly interact with the immune system as neoantigens.A large number of clinical and experimental studies reveal that preservatives in topical ophthalmic medications have been demonstrated to produce effects from inflammation/ hypersensitivity to permanent cytotoxic effects involving all structures of the eye.

    View details for DOI 10.1097/ACI.0b013e3283306990

    View details for Web of Science ID 000269511100009

    View details for PubMedID 19697451